The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

Conversation with The Cancer Letter

Novartis’s Hirawat: “It’s a continuous dialogue that goes on on a daily basis”

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
BYLINEDOWNLOAD PDFTABLE OF CONTENTS

The two FDA pilot programs—Real-Time Oncology Review and Assessment Aid sped up the processing of Novartis’s supplemental new drug applications for Kisqali (ribociclib), said Samit Hirawat, executive vice president and head of Global Oncology at Novartis.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Byline
Paul Goldberg
Editor & Publisher
Table of Contents

YOU MAY BE INTERESTED IN

AACR Cancer Progress Report makes the case for federal investment in cancer research

As NCI and NIH funding is being deliberated in Congress, this year’s 2025 AACR Cancer Progress Report had an unequivocal message: With 20 new anticancer therapeutics, new uses for eight previously approved anticancer therapeutics, two new early detection tools, and several AI-powered diagnostics approved over the span of just one year, cancer research funding yields a good return on investment. 
By Sara Willa Ernst
Byline
Paul Goldberg
Editor & Publisher
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account